EOLS - Evolus stock rises as Q1 revenue soars 177% Y/Y

Evolus (NASDAQ:EOLS) stock rose ~11% May 11 after the company's Q1 results beat analysts' estimates on May 10 post-market. The performance beauty company — which makes Jeuveau, a rival product of AbbVie's Botox for frown lines — saw its total net revenues rise by +177% Y/Y to $33.91M. The company said the increase was driven mainly by higher volumes and a slightly higher average selling price. "Our sales for the first quarter of 2022 were well above the estimated U.S. neurotoxin market growth rate. Over the past year, we have accelerated the pace of new account additions and achieved a record number of patient redemptions in our consumer loyalty rewards program," said Evolus (EOLS) President and CEO David Moatazedi. The company said gross profit margin and adjusted gross profit margin were 58.9% and 61.0%, respectively, both  were impacted by higher settlement royalty rates in effect until September 2022. Net loss widened to -$17.50M, compared to

For further details see:

Evolus stock rises as Q1 revenue soars 177% Y/Y